GlassScriptPhysician profile
Jason Charles Viereck
NPI 1205898202
$5,096.27
in general payments reported to CMS, 2019-2025
32 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,335 · 2020: $203 · 2021: $278 · 2022: $398 · 2023: $370 · 2024: $227 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,594.02 | 2019 | |
| Abbvie INC. | $763.49 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Allergan, INC. | $290.39 | 2019-2022 | |
| Livanova USA, INC. | $204.27 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $176.11 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $113.02 | 2019 | |
| Eisai INC. | $88.62 | 2019 | |
| Genzyme Corporation | $70.00 | 2019 | |
| Genentech USA, INC. | $61.99 | 2019-2025 | Ocrevus Zunovo |
| Lundbeck LLC | $57.26 | 2023 | Vyepti |
| Pfizer INC. | $55.47 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $51.51 | 2019 | |
| Merz North America, INC. | $50.00 | 2019 | |
| Neurelis, INC. | $49.78 | 2020-2023 | Valtoco |
| Biogen, INC. | $44.78 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adamas Pharmaceuticals, INC. | $42.35 | 2019-2021 | |
| Horizon Therapeutics Plc | $40.36 | 2021 | |
| Sk Life Science, INC. | $38.28 | 2022-2023 | |
| Tg Therapeutics, INC. | $36.38 | 2025 | |
| Alexion Pharmaceuticals, INC. | $27.49 | 2020 | |
| Grifols USA, LLC | $27.30 | 2020 | |
| Vanda Pharmaceuticals INC. | $25.16 | 2025 | Ponvory |
| Acorda Therapeutics, INC | $24.50 | 2019 | |
| Argenx US, INC. | $23.88 | 2023 | Vyvgart |
| Celgene Corporation | $23.83 | 2023 | Zeposia |
| Acadia Pharmaceuticals INC | $22.79 | 2019 | |
| Cala Health, INC. | $21.61 | 2023 | Cala Trio |
| Ucb, INC. | $20.88 | 2019 | |
| Amgen INC. | $19.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.86 | 2024 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $12.98 | 2021 | |
| Travere Therapeutics, INC. | $0.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Viereck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.